Our experience

Using our experience to shape the future of health care.

Our experience plays a huge part in why we are BioSpecialized. A sum of our manufacturing and supply network, and oncology experience, we have applied this expertise to biosimilar treatments.

And now we are getting ready to bring the benefits of biosimilars to you and your patients:

  • In 2012, the biosimilars business unit was established within the biopharmaceutical development/production network of Merck KGaA
  • In 2017, Fresenius Kabi strategically acquired the biosimilar business unit of market leader Merck KGaA, with a pipeline focusing on oncology and autoimmune disease
  • Fresenius Kabi has successfully launched biosimilars in Europe (2019), Canada (2021) and Australia (2021)
  • We are committed to launching oncology and immunology biosimilars in the U.S.

With all this and more, we are continually committed to making affordable, high-quality health care available to more patients coping with critical and chronic diseases. Because that’s what a BioSpecialized future looks like.

Manufacturing and supply network

Why and how we aim to make treatments available to everyone.

Our awards

A celebration of our achievements.

Oncology experience

Discover a rich portfolio developed over a quarter of a century.

Our biosimilar pipeline

What you can expect from us in the future.


Looking for more information?

If you would like to know more about Fresenius Kabi and our unique approach to biosimilars, please get in touch.

Contact Us
Fresenius Kabi

Fresenius Kabi AG © June 2021 1702-BIOS-08-05/21